Psyence Biomedical Ltd
psyencebiomed.comWhat Do They Do?
Develops nature-derived psychedelic drug candidates for mental health conditions, with clinical research focused on natural psilocybin for adjustment disorder in cancer palliative care.
20-F for FY2026, filed Jun 22, 2026The Company is a multi-asset, vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, with…View ↗
We strive to set the global standard for excellence and consistency in drug development using nature-based psilocybin products. Psyence’s…View ↗
The product to be used in this Phase IIb Study will be the proprietary botanical drug candidate NPX-5 (25mg), which Psyence sources from…View ↗
Loading...
